References
- Andrews AM, Lutton EM, Cannella LA, et al. (2018). Characterization of human fetal brain endothelial cells reveals barrier properties suitable for in vitro modeling of the BBB with syngenic co-cultures. J Cereb Blood Flow Metab 38:888–903.
- Bishayee A, Sethi G. (2016). Bioactive natural products in cancer prevention and therapy: progress and promise. Semin Cancer Biol 40–41:1–3.
- Cheng M, Zhang ZW, Ji XH, et al. (2020). Super-enhancers: a new frontier for glioma treatment. Biochim Biophys Acta Rev Cancer 1873:188353.
- Chen Y, Mi Y, Zhang X, et al. (2019). Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells. J Exp Clin Cancer Res 38:402.
- Chen Z, Zhao P, Luo Z, et al. (2016). Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano 10:10049–57.
- De Witt Hamer PC, De Witt Hamer PC, Klein M, et al. (2021). Functional outcomes and health-related quality of life following glioma surgery. Neurosurgery 88:720–32.
- Deng J, Wu Z, Zhao Z, et al. (2020). Berberine-loaded nanostructured lipid carriers enhance the treatment of ulcerative colitis. Int J Nanomedicine 15:3937–51.
- Ding P, Wang Z, Wu Z, et al. (2020). Natural biointerface based on cancer cell membranes for specific capture and release of circulating tumor cells. ACS Appl Mater Interfaces 12:20263–70.
- Ganganboina AB, Dega NK, Tran HL, et al. (2021). Application of sulfur-doped graphene quantum dots@gold-carbon nanosphere for electrical pulse-induced impedimetric detection of glioma cells. Biosens Bioelectron 181:113151.
- Gao H. (2016). Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 6:268–86.
- Gao H. (2017). Perspectives on dual targeting delivery systems for brain tumors. J Neuroimmune Pharmacol 12:6–16.
- Gu G, Hu Q, Feng X, et al. (2014). PEG–PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy. Biomaterials 35:8215–26.
- Hayat SMG, Bianconi V, Pirro M, et al. (2020). CD47: role in the immune system and application to cancer therapy. Cell Oncol 43:19–30.
- Huo T, Yang Y, Qian M, et al. (2020). Versatile hollow COF nanospheres via manipulating transferrin corona for precise glioma-targeted drug delivery. Biomaterials 260:120305.
- Jaraiz-Rodriguez M, Talaveron R, Garcia-Vicente L, et al. (2020). Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo. Neuro Oncol 22:493–504.
- Jin J, Krishnamachary B, Barnett JD, et al. (2019). Human cancer cell membrane-coated biomimetic nanoparticles reduce fibroblast-mediated invasion and metastasis and induce T-cells. ACS Appl Mater Interfaces 11:7850–61.
- Kumar R, Singh M, Meena J, et al. (2019). Hyaluronic acid–dihydroartemisinin conjugate: synthesis, characterization and in vitro evaluation in lung cancer cells. Int J Biol Macromol 133:495–502.
- Layek B, Sadhukha T, Prabha S. (2016). Glycoengineered mesenchymal stem cells as an enabling platform for two-step targeting of solid tumors. Biomaterials 88:97–109.
- Li Y, Song Y, Zhang W, et al. (2020). MOF nanoparticles with encapsulated dihydroartemisinin as a controlled drug delivery system for enhanced cancer therapy and mechanism analysis. J Mater Chem B 8:7382–9.
- Liu L, Wei Y, Zhai S, et al. (2015a). Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy. Biomaterials 62:35–46.
- Liu Q, Zhang C, Yuan J, et al. (2015b). PTK7 regulates Id1 expression in CD44-high glioma cells. Neuro Oncol 17:505–15.
- Lu L, Zhao X, Fu T, et al. (2020). An iRGD-conjugated prodrug micelle with blood–brain-barrier penetrability for anti-glioma therapy. Biomaterials 230:119666.
- Muller RH, Petersen RD, Hommoss A, Pardeike J. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59:522–30.
- Pan Y, Lu F, Fei Q, et al. (2019). Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. J Hematol Oncol 12:124.
- Pierluigi T, Szilárd T, Nóra E, et al. (2018). Development of novel cyclic NGR peptide–daunomycin conjugates with dual targeting property. Beilstein J Org Chem 14:911–8.
- Que X, Su J, Guo P, et al. (2019). Study on preparation, characterization and multidrug resistance reversal of red blood cell membrane-camouflaged tetrandrine-loaded PLGA nanoparticles. Drug Deliv 26:199–207.
- Que Z, Wang P, Hu Y, et al. (2017). Dihydroartemisin inhibits glioma invasiveness via a ROS to P53 to β-catenin signaling. Pharmacol Res 119:72–88.
- Roedig H, Damiescu R, Zeng-Brouwers J, et al. (2020). Danger matrix molecules orchestrate CD14/CD44 signaling in cancer development. Semin Cancer Biol 62:31–47.
- Ruan S, Zhou Y, Jiang X, Gao H. (2021). Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release. Adv Sci 8:2004025.
- Seidi K, Jahanban-Esfahlan R, Monhemi H, et al. (2018). NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth. Oncogene 37:3967–80.
- Shi J, Xiao Z, Kamaly N, Farokhzad OC. (2011). Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 44:1123–34.
- Srinivasan B, Kolli AR, Esch MB, et al. (2015). TEER measurement techniques for in vitro barrier model systems. J Lab Autom 20:107–26.
- Sun Q, Wu J, Jin L, et al. (2020). Cancer cell membrane-coated gold nanorods for photothermal therapy and radiotherapy on oral squamous cancer. J Mater Chem B 8:7253–63.
- Suski JM, Lebiedzinska M, Wojtala A, et al. (2014). Isolation of plasma membrane-associated membranes from rat liver. Nat Protoc 9:312–22.
- Tan J, Duan X, Zhang F, et al. (2020). Theranostic nanomedicine for synergistic chemodynamic therapy and chemotherapy of orthotopic glioma. Adv Sci 7:2003036.
- Thakur A, Xu C, Li WK, et al. (2021). In vivo liquid biopsy for glioblastoma malignancy by the AFM and LSPR based sensing of exosomal CD44 and CD133 in a mouse model. Biosens Bioelectron 191:113476.
- Vainshtein I, Schneider AK, Sun B, et al. (2016). Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals. Cytometry B Clin Cytom 90:128–40.
- Valentinis B, Porcellini S, Asperti C, et al. (2019). Mechanism of action of the tumor vessel targeting agent NGR-hTNF: role of both NGR peptide and hTNF in cell binding and signaling. Int J Mol Sci 20:4511.
- Wan X, Zhong H, Pan W, et al. (2019). Programmed release of dihydroartemisinin for synergistic cancer therapy using a CaCO3 mineralized metal-organic framework. Angew Chem Int Ed Engl 58:14134–9.
- Wu M, Liu X, Bai H, et al. (2019). Surface-layer protein-enhanced immunotherapy based on cell membrane-coated nanoparticles for the effective inhibition of tumor growth and metastasis. ACS Appl Mater Interfaces 11:9850–9.
- Xiao Z, Morris-Natschke SL, Lee KH. (2016). Strategies for the optimization of natural leads to anticancer drugs or drug candidates. Med Res Rev 36:32–91.
- Yu M, Yuan W, Li D, et al. (2019). Predicting drug release kinetics from nanocarriers inside dialysis bags. J Control Release 315:23–30.
- Zhai M, Wang Y, Zhang L, et al. (2018). Glioma targeting peptide modified apoferritin nanocage. Drug Deliv 25:1013–24.
- Zhang W, He H, Liu J, et al. (2013). Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials 34:306–19.
- Zhao Q, Chen W, Chen Y, et al. (2011). Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjug Chem 22:346–52.
- Zhao Z, Ji M, Wang Q, et al. (2020). Ca2+ signaling modulation using cancer cell membrane coated chitosan nanoparticles to combat multidrug resistance of cancer. Carbohydr Polym 238:116073.
- Zhy A, Xmj A, Myh A, et al. (2021). Regulation of CD47 expression by interferon-gamma in cancer cells. Transl Oncol 14:101162.